Skip to main content

Table 4 Independent predictors for the achievement of LDA at 24 weeks in multivariable analysis

From: Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis

  Tofacitinib Baricitinib
Variables Univariate model Multivariable model Univariate model Multivariable model
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Age (per 1-year increase) 0.997 (0.969–1.026) 0.838   0.987 (0.951–1.023) 0.462  
Disease duration (per 1-year increase) 0.999 (0.965–1.034) 0.944   0.965 (0.919–1.014) 0.153  
Concomitant MTX use (yes/no) 1.02 (0.499–2.085) 0.957   1.869 (0.770–4.535) 0.165  
Concomitant oral steroid use (yes/no) 0.403 (0.203–0.799) 0.008* 0.470 (0.232–0.953) 0.035* 0.412 (0.167–1.013) 0.050 0.339 (0.102–1.129) 0.073
Number of previous use of b/tsDMARDs (per drug) 0.882 (0.714–1.09) 0.240   0.687 (0.522–0.905) 0.005* 0.700 (0.504–0.971) 0.026*
Inadequate response of another JAK inhibitor (yes/no)      0.511 (0.194–1.341) 0.167  
DAS28-ESR at baseline (per 1 increase) 0.798 (0.628–1.014) 0.061 0.882 (0.678–1.147) 0.345 0.395 (0.247–0.633) < 0.001* 0.395 (0.225–0.694) < 0.001*
mHAQ (per 1 increase) 0.603 (0.366–0.996) 0.039* 0.745 (0.424–1.304) 0.294 0.322 (0.155–0.667) < 0.001* 0.697 (0.301–1.611) 0.396
ACPA positive (yes/no) 1.286 (0.568–2.912) 0.543   0.426 (0.138–1.314) 0.131  
RF positive (yes/no) 1.687 (0.733–3.886) 0.207   0.429 (0.115–1.599) 0.198  
  1. OR odds ratio, 95% CI 95% confidence interval, MTX methotrexate, b/tsDMARDs biological and/or targeted synthetic disease-modifying antirheumatic drugs, JAK Janus kinase, DAS disease activity score, mHAQ modified Health Assessment Questionnaire, ESR erythrocyte sedimentation rate, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor
  2. *P < 0.05